GIMV also at the origin of largest biotech IPO ever on Euronext Brussels
GIMV is proud to announce that Ablynx managed to realise the largest biotech IPO on Euronext Brussels ever. GIMV, an Ablynx shareholder from the start, has acquired through different capital rounds 3 ,414,979 Ablynx shares, or 14.21 percent of the nondiluted share capital before the IPO. Since only new shares have been issued on the occasion of the IPO, the existing shareholders did not sell any shares. The introduction price is set at EUR 7.0 per share.
Ablynx, the biopharmaceutical company focusing on the discovery and development of Nanobodies®, announced today that it has successfully completed its initial public offering (IPO) and is listed as of tomorrow on the Eurolist by Euronext Brussels. Ablynx was founded by GIMV, Biotech Fonds Vlaanderen (which is managed by GIMV) and VIB (Flemish Institute for Biotechnology). GIMV and Biotech Fonds Vlaanderen together hold 24.01% (before IPO), which makes them the largest shareholder.
- On the occasion of the Ablynx IPO GIMV has not sold any shares;
- The introduction price is set at EUR 7.0 per share;
- GIMV and Biotech Fonds Vlaanderen took advantage of the attractive introduction price to increase their investment in Ablynx;
- GIMV has committed itself not to sell any Ablynx share it already had before the IPO during at least 6 month period (lock-up agreement).
Ablynx is a beautiful example of how GIMV has put venture capital at the disposal of starting Flemish biotechnological companies with international ambitions. Other successful investments of GIMV and Biotech Fonds Vlaanderen in Flemish biotech start-ups are Devgen, CropDesign, Plant Genetic Systems and Innogenetics. Recently, GIMV and Biotech Fonds Vlaanderen also invested in ActoGenix, Movetis, ThromboGenics and Pronota. Just like Ablynx these companies can count on the financial means, the expertise and the international network of GIMV right from the start. Being Ablynx shareholder from the start, GIMV is very proud about the successful introduction of Ablynx on the stock exchange.
For more information, please contact:
Mr. Frank De Leenheer - Investor Relations & Corporate Communications Manager GIMV
Tel: +32 3 290 22 18 - E-mail: firstname.lastname@example.org
Mr. Frank Bulens – Executive Investment Manager GIMV
Tel: +32 3 290 21 57 – E-mail: email@example.com